usbureau food drug administr usbureau rindock docket 94n0171 rindock discoveri experiment develop inc deprenyl gelatin capsul liquid deprenyl citrat propos refus approv new drug applic opportun hear agenc agenc food drug administr hh agenc action action notic action summari summari food drug administr fda propos disapprov new drug applic nda deprenyl deprenyl citrat deprenyl submit discoveri experiment develop inc 29949 r 54 west wesley chapel fl 33543 discoveri fda also provid discoveri notic opportun hear propos ground fda propos refus approv numer importantli fda conclud insuffici inform determin whether discoveri deprenyl citrat safe use effect purport repres condit use prescrib recommend suggest propos label discoveri deprenyl citrat intend treatment alzheim diseas summari date date hear request due june 30 1994 data inform support hear request due juli 18 1994 date address address request hear support data comment identifi docket 94n0171 submit docket manag branch hfa305 food drug administr rm 123 12420 parklawn dr rockvil md 20857 address inform contact megan l foster center drug evalu research hfd366 food drug administr 7500 standish pl rockvil md 20855 3015942041 supplem supplementari inform background discoveri submit nda deprenyl citrat propos label treatment alzheim diseas throughout document drug product refer deprenyl citrat deprenyl occasion especi refer activ drug substanc term selegilin use consist term claim made nda nda anoth deprenyl product selegilin hydrochlorid eldepryl reg held somerset pharmaceut inc somerset approv june 5 1989 treatment parkinson diseas somerset product l deprenyl levorotatori acetylen deriv phenethylamin discoveri claim four distinct function deprenyl help curb delay effect alzheim diseas could well delay onset diseas taken prevent function 1 deprenyl caus bodi natur produc dopamin normal deplet age turn assist maintain healthi brain cell function 2 deprenyl block toxic free radic break dopamin caus degener brain cell function 3 deprenyl reviv malfunct dormant brain cell bring back lost bodi function function 4 deprenyl increas bodi hormon content improv bodi motor immun system novemb 29 1991 discoveri submit nda 20242 data inform intend demonstr deprenyl citrat safeti effect treatment alzheim diseas propos product market without prescript discoveri submit minor amend decemb 6 1991 provid updat tabl content revis page nda januari 17 1992 fda notifi discoveri letter nda accept file 21 cfr 314 101 nda suffici complet permit substant review fda describ numer defici attach letter respons fda refus file discoveri request inform confer fda held novemb 16 1992 letter discoveri date novemb 24 1992 fda notifi discoveri option amend applic 21 cfr 314 101 3 file protest discoveri decemb 7 1992 letter date decemb 31 1992 fda acknowledg discoveri request file protest state applic would review file letter date februari 9 1993 discoveri object advic given fda letter novemb 24 decemb 31 1992 nda file protest may amend file letter discoveri date august 20 1993 fda conclud inform present discoveri inadequ applic approv 21 cfr 314 120 discoveri respond letter date septemb 1 1993 request time extens 180 day 21 cfr 314 120 5 consid option regard applic fda grant request letter date march 1 1994 receiv fda march 7 1994 discoveri request opportun hear 21 cfr 314 120 3 question whether ground deni approv nda 20242 ii defici nda 20242 discoveri requir submit among thing full report investig made show whether drug safe use whether drug effect use section 505 b 1 feder food drug cosmet act act 21 u c 355 b 1 well inform requir 21 cfr 314 50 discoveri nda 20242 provid insuffici inform determin whether deprenyl gelatin capsul liquid safe fail includ adequ test method reason applic show whether deprenyl gelatin capsul liquid safe nda lack substanti evid deprenyl gelatin capsul liquid effect repres method use facil control use manufactur process pack deprenyl gelatin capsul liquid inadequ preserv ident strength qualiti puriti section 505 act addit discoveri nda 20242 fail includ adequ environment assess fail includ proper label bioavail data fail demonstr complianc current good manufactur practic regul detail descript defici follow safeti deprenyl section 505 act 21 cfr 314 125 b 2 b 4 discoveri fail includ nda 20242 adequ test method reason applic show whether deprenyl gelatin capsul liquid safe use condit prescrib recommend suggest propos label suffici inform deprenyl gelatin capsul liquid determin whether safe use condit prescrib recommend suggest propos label 1 preclin data discoveri fail includ either report complet rang studi necessari assess pharmacolog toxicolog profil drug 21 cfr 314 50 clinic data obviat need studi discoveri fail includ requir toxicolog studi 1 acut subacut studi rodent nonrod 2 chronic studi consist 6 month rodent 12 month nonrod studi 3 genotox screen 4 studi examin effect drug reproduct 5 carcinogen studi 21 cfr 314 50 2 exampl type materi fda would review describ guidelin format content nonclin pharmacolog toxicolog section applic 2 clinic data note selegilin hydrochlorid l deprenyl current market eldepryl reg somerset treatment parkinson diseas exclus period applic expir june 6 1994 fda could review nda 20242 applic submit section 505 b 1 act exclus period eldepryl reg expir applic submit section 505 b 2 section 505 j act refer eldepryl reg approv nda 20242 discoveri attempt use previou approv somerset selegilin hydrochlorid product evid safeti deprenyl citrat product mere fact approv may howev use way section 505 b 1 act requir discoveri submit full report investig made show product safe safeti studi eldepryl reg avail discoveri use satisfi requir moreov discoveri claim deprenyl purer potent effect eldepryl reg true differ could reflect among thing increas absorpt rate absorpt increas concentr rate transmiss drug brain greater potenti advers event nda 20242 safeti studi perform use discoveri product studi compar bioavail discoveri product eldepryl reg accordingli fda cannot assess safeti b effect deprenyl section 505 act 21 cfr 314 125 b 5 discoveri fail provid nda 20242 substanti evid consist adequ well control studi deprenyl gelatin capsul liquid effect repres condit use prescrib recommend suggest propos label propos label discoveri applic claim deprenyl citrat demonstr quantit qualit improv cognit function alzheim patient result inhibit maob activ support claim discoveri includ reprint 171 articl medic scientif literatur although articl pertain deprenyl one studi use discoveri product product known bioavail relationship discoveri product discoveri identifi 12 171 articl evid effect deprenyl citrat treatment alzheim diseas notic discuss first articl greater detail other mani characterist well control studi report submit supplement addit inform might qualifi adequ well control studi support effect deprenyl drug product treatment alzheim diseas remain 11 studi inher incap regard substanti evid effect deprenyl citrat treatment alzheim diseas therefor summar briefli 1 mangoni et al effect maob inhibitor treatment alzheim diseas european neurolog 31 100107 1991 design one hundr thirti six patient mild moder alzheim type disord enrol 3 month random doubl blind placebo control trial evalu baselin month 1 2 3 enrol patient 17 drop follow random first effect assess articl report number group origin random creat two group approxim equal size e 68 group base number remain group end studi virtual 17 drop out would seem placebo group seven three deprenyl four placebo complet 3 month therapi explan given 17 earli drop out appar imbal seven later patient discontinu poor efficaci two deprenyl patient four placebo patient poor complianc one deprenyl patient thu imbal number patient treat analyz 65 l deprenyl 10 milligram per day 47 placebo patient includ final analysi effect effect measur conduct follow prefix sequenc 1 bless dementia scale 2 digit span wechsler memori scale wm 3 raskin crook inventori psychic somat complaint elderli 4 short stori wm _immedi recal 5 simpl copi draw 6 toulous pieron attent test 7 facilit copi draw 8 short stori wm _delay recal 9 word fluenci measur taken baselin end first second third month ii result base analysi varianc treatment includ four test occas statist signific differ report favor l deprenyl placebo measur except one portion toulous pieron attent test iii discuss taken face valu result publish studi suggest posit effect l deprenyl patient alzheim diseas howev publish report lack mani detail need assess studi thu studi publish without addit inform cannot contribut fulfil statutori requir substanti evid effect discoveri fail provid data bioequival studi demonstr rate extent absorpt product essenti ident product manufactur chiesi farmaceutici p parma itali use mangoni studi 21 cfr 320 21 314 126 b protocol avail review determin design analysi includ analysi patient complet studi perform propos 21 cfr 314 50 314 126 b 1 c measur specif procedur minim bia e g detail random blind mainten patient assign code describ explan larg imbal initi dropout given 21 cfr 314 126 b 5 case report form data tabul individu patient data safeti effect measur provid 21 cfr 314 50 314 126 2 knoll j j dallo yen striatal dopamin sexual activ lifespan longev rat treat deprenyl life scienc 45 525531 1989 studi adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas studi rat clinic studi 21 u c 355 see 21 cfr 314 126 passim 3 heinonen e h et al pharmacokinet metabol selegilin acta neurologica scandinavia 126 9399 1989 studi adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas clear object studi studi pharmacokinet effect selegilin deprenyl 21 u c 355 see 21 cfr 314 126 passim 4 shoulson et al parkinson studi group effect deprenyl progress disabl earli parkinson diseas new england journal medicin 321 13641370 1992 studi adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas studi parkinson alzheim diseas see e g 21 cfr 314 126 b 6 5 tariot p n et al cognit effect l deprenyl alzheim diseas psychopharmacolog 91 489495 1987 allegedli doubl blind studi 17 patient adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas protocol avail provid detail 21 cfr 314 126 b 1 despit lack protocol clear studi use random concurr control 21 cfr 314 126 b 2 mean assur compar treatment control group 21 cfr 314 126 b 3 procedur minim bia blind describ 21 cfr 314 126 b 5 test drug identifi 21 cfr 314 126 6 tariot p n et al l deprenyl alzheim diseas preliminari evid behavior chang monoamin oxidas b inhibit archiv gener psychiatri 44 427433 1987 preliminari report data tariot studi describ immedi 7 tariot p n et al tranylcypromin compar l deprenyl alzheim diseas journal clinic psycho pharmacolog 8 2327 1988 seven patient studi adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas primari purpos investig tranylcypromin drug unknown effect treatment alzheim diseas see e g 21 cfr 314 126 b 2 iv 8 sunderland et al dose depend effect deprenyl csf monoamin metabolit patient alzheim diseas psychopharmacolog 91 293296 1987 studi adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas clear object studi studi pharmacokinet effect deprenyl 21 u c 355 see 21 cfr 314 126 passim 9 konradi c p rieder b h youdim hydrogen peroxid enhanc activ monoamin oxidas type b type pilot studi journal neural transmiss suppl 22 6173 1986 studi adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas primari purpos studi effect certain tissu hydrogen peroxid deprenyl citrat clinic studi e studi human patient diseas intend treat 21 u c 355 see 21 cfr 314 126 passim 10 maurizi c p therapeut potenti tryptophan melatonin possibl role depress sleep alzheim diseas abnorm age medic hypothes 31 233242 1990 review articl adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas report investig moreov even mention deprenyl selegilin 21 u c 355 see 21 cfr 314 126 passim 11 knoll j deprenyl medic strategi modul age relat declin striatal dopaminerg system journal american geriatr societi 40 839847 1992 review articl adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas report investig 21 u c 355 see 21 cfr 314 126 passim 12 martini e et al brief inform earli phase ii studi deprenyl dement patient pharmacopsychiatri 20 256257 1987 11 patient uncontrol studi adequ well control clinic studi effect deprenyl citrat treatment alzheim diseas inter alia report investig permit valid comparison control 21 cfr 314 126 b 2 c method facil control use discoveri discoveri applic approv section 505 act 21 cfr 314 125 b 1 method use facil control use manufactur process pack hold drug substanc drug product inadequ preserv ident strength qualiti puriti stabil bioavail 1 drug substanc applic fail contain adequ inform concern method use synthesi extract isol purif new drug substanc determin ident strength qualiti puriti mani item inform requir 21 cfr 314 50 1 absent nda 20242 includ limit follow full descript physic chemic characterist drug substanc includ adequ proof structur stereochemistri character selegilin base citrat claim applic uniqu drug substanc includ element analysi infra red spectroscopi ultraviolet spectroscopi 1h 13c nuclear magnet reson suitabl determin character coupl peak posit peak pattern specif ident test citrat suitabl studi demonstr 1 1 citrat salt actual form exampl type materi fda would review describ guidelin submit support document drug applic manufactur drug substanc pp 35 addit nda includ physic data selegilin citrat certif analysi complet test propos specif exampl type materi fda would review describ guidelin submit sampl analyt data method valid p 5 ii adequ descript method synthesi applic lack manufactur procedur master batch formula quantiti exampl type materi fda would review describ guidelin submit support document drug applic manufactur drug substanc e g pp 1118 discoveri argument manufactur selegilin base patent process expir 1985 obviat need discoveri submit complet manufactur inform inform requir regardless whether patent expir iii list process control describ method use determin complet reaction exampl type materi fda would review describ guidelin submit support document drug applic manufactur drug substanc pp 2936 iv descript reagent solvent materi use synthesi drug substanc exampl type materi fda would review describ guidelin submit support document drug applic manufactur drug substanc p 10 v descript contain closur system storag ship drug substanc applic provid name manufactur compon letter author manufactur drug master file exampl type materi fda would review describ guidelin format content chemistri manufactur control section applic pp 45 see also 21 cfr 314 420 b 2 drug product compon composit formul applic identifi establish name complet chemic name substanc use compon drug product includ substanc use synthesi extract method prepar new drug substanc specif area inform pertain drug product compon composit formul requir 21 cfr 314 50 1 ii absent nda 20242 includ follow 1 list compon use manufactur drug product 2 statement composit drug product 3 statement specif analyt method compon even unclear applic dosag form discoveri intend manufactur test absent applic includ specif ident test chiral ident test chiral puriti test assay drug substanc dissolut test test necessari permit fda make assess drug product ii drug product manufactur applic fail contain descript manufactur packag procedur process control drug product also absent method sampl qualiti assur 21 cfr 314 50 1 ii exampl type materi fda would review describ guidelin submit document manufactur control drug product pp 47 iii drug product laboratori method applic fail includ specif analyt method necessari assur ident strength qualiti puriti drug product 21 cfr 314 50 1 ii particular fail includ full descript laboratori method use check lot finish drug product sampl method procedur rational sampl plan provid regulatori specif test method drug product also provid exampl type materi fda would review describ guidelin submit document manufactur control drug product pp 78 iv drug product contain system packag control applic fail provid adequ inform respect characterist test method employ contain closur compon part drug packag assur suitabl intend use descript packag procedur process control drug product includ contain closur system use drug product even describ 21 cfr 314 50 1 ii exampl type materi fda would review describ guidelin submit document packag human drug biolog 3 method valid discoveri applic fail includ adequ laboratori test procedur assur finish drug product drug substanc conform appropri standard ident strength qualiti puriti valid test method perform actual sampl full inform pertain sampl submit nda time applic 21 cfr 314 50 1 ii exampl type materi fda would review describ guidelin submit sampl analyt data method valid 4 refer standard applic lack inform refer standard sampl standard activ ingredi claim selegilin citrat selegilin base necessari physic chemic properti refer standard describ ensur integr serv 21 cfr 314 50 e 1 c exampl type materi fda would review describ guidelin submit sampl analyt data method valid p 6 5 stabil applic fail includ full descript data deriv studi stabil drug stabil drug product demonstr contain closur system propos use 21 cfr 314 50 1 ii see also 21 cfr 211 166 exampl type materi fda would review describ guidelin submit document stabil human drug biolog 6 establish locat applic fail identifi show locat establish conduct part manufactur process packag label oper 21 cfr 314 50 1 1 ii exampl type materi fda would review describ guidelin submit document manufactur control drug product p 4 applic lack clear delin oper perform person discoveri exampl contract facil use encapsul drug substanc solut identifi submiss 7 environment assess complet satisfactori environment assess requir 21 cfr 25 22 14 314 50 1 iii failur submit adequ environment assess ground fda refus approv nda 21 cfr 25 22 b nda must contain either claim categor exclus 21 cfr 25 24 environment assess 21 cfr 25 31a discoveri environment assess claim exclus consist one paragraph statement facial unrespons requir 21 cfr 25 31a exampl environment assess nda 20242 provid identif chemic substanc subject propos action label deprenyl applic approv section 505 act well 21 cfr 314 125 b 8 propos label compli requir label label set forth 21 cfr part 201 21 cfr 314 50 propos label fail meet statutori regulatori requir numer way includ limit follow 1 label use packag drug product provid applic 21 cfr 314 50 e 2 ii 2 label use shipment storag bulk drug substanc see 21 cfr 201 122 well label requir demonstr complianc current good manufactur practic cgmp regul see e g 21 cfr 211 122 provid applic 3 proprietari name design drug product properli accompani proper establish name drug substanc label label drug product 21 cfr 201 10 g 1 furthermor name deprenyl base hydrochlorid citrat salt accept establish name drug see 21 cfr 299 4 e bioavail bioequival deprenyl applic approv section 505 act 21 cfr 314 125 b 9 contain bioavail bioequival data requir 21 cfr part 320 applic must contain either follow 1 evid demonstr vivo bioavail drug product 2 inform would permit agenc waiv demonstr vivo bioavail discoveri submit neither therefor fulfil requir human pharmacokinet bioavail section nda requir 21 cfr 314 50 3 320 21 discoveri contend entitl waiver demonstr vivo bioavail drug metabolit measur plasma design level content incorrect shown two articl provid inform metabolit see salonen j determin amin metabolit selegilin biolog fluid capillari ga chromatographi journal chromatographi 527 163168 1990 heinonen e h r lammintausta review pharmacolog selegilin acta neurologica scandinavia suppl 136 4459 1990 discoveri also state applic ue stereospecif low cerebrospin fluid concentr l amphetamin metabolit recov trial metabolit contribut clinic efficaci deprenyl pose risk patient extend use statement substanti discoveri applic taken part earlier articl heinonen heinonen e h et al pharmacokinet metabol selegilin acta neurologica scandinavia 126 9399 1989 odd inform describ 1990 articl heinonen state desmethylselegilin may contribut pharmacolog activ selegilin treatment f discoveri complianc cgmp applic approv section 505 act 21 cfr 314 125 b 13 method use facil control use manufactur process pack hold drug substanc drug product compli cgmp regul 21 cfr part 210 211 februari 25 march 2 1993 fda investig made inspect discoveri establish wesley chapel fl observ numer violat cgmp regul follow among numer cgmp violat observ februari march 1993 inspect 1 discoveri lack adequ standard oper procedur regard respons qualiti control unit 21 cfr 211 22 ii clean mainten equip use manufactur product 21 cfr 211 67 iii receipt handl compon 21 cfr 211 82 iv product process control e g weigh compon 21 cfr 211 101 v process control test 21 cfr 211 110 2 discoveri lack written stabil program addit discoveri could locat record document stabil test selegilin citrat 21 cfr 211 166 3 discoveri could produc batch product record show manufactur one batch produc intend firm use clinic trial 21 cfr 211 188 verifi subsequ inspect discoveri oper complianc cgmp regul 21 cfr part 210 211 agenc cannot conclud method facil control use product propos drug product adequ assur ident strength qualiti puriti drug product g conclus fda propos refus approv discoveri nda 20242 ground discoveri fail provid adequ evid safeti effect proper method facil control environment assess proper label bioavail data complianc cgmp regul discoveri fail submit appropri studi inform necessari approv product iii notic opportun hear director center drug evalu research director evalu inform discuss ground state propos refus approv nda 20242 therefor notic given discoveri interest person director propos issu order section 505 act refus approv nda 20242 director find 1 investig report requir submit pursuant 21 u c 355 b includ adequ test method reason applic show whether discoveri deprenyl citrat product safe use condit prescrib recommend suggest propos label thereof 2 result test show discoveri deprenyl citrat product safe use condit 3 method use facil control use manufactur process packag discoveri deprenyl citrat product inadequ preserv ident strength qualiti puriti 4 upon basi inform submit director part applic upon basi inform director respect discoveri deprenyl citrat product director insuffici inform determin whether discoveri deprenyl citrat product safe use condit 5 evalu basi inform submit director part applic inform director respect discoveri deprenyl citrat product lack substanti evid drug effect purport repres condit use prescrib recommend suggest propos label thereof 6 base fair evalu materi fact propos label fals mislead accord section 505 act 21 cfr part 314 applic herebi given opportun hear show approv nda refus applic decid seek hear shall file 1 june 20 1994 written notic appear request hear 2 juli 18 1994 data inform analys reli demonstr genuin issu materi fact justifi hear specifi 21 cfr 314 200 interest person may also submit comment notic procedur requir govern notic opportun hear notic appear request hear inform analys justifi hear comment grant denial hear contain 21 cfr 314 200 21 cfr part 12 failur applic file time written notic appear request hear requir 21 cfr 314 200 constitut elect person use opportun hear concern propos action waiver content concern legal statu person drug product new drug product market without approv nda subject regulatori action time request hear may rest upon mere alleg denial must present specif fact show genuin substanti issu fact requir hear conclus appear face data inform factual analys request hear genuin substanti issu fact preclud refus approv applic request hear made requir format requir analys commission food drug enter summari judgment person request hear make find conclus deni hear submiss pursuant notic opportun hear file four copi except data inform prohibit public disclosur 21 u c 331 j 18 u c 1905 submiss may seen docket manag branch address 9 4 p monday friday notic issu feder food drug cosmet act sec 505 21 u c 355 author deleg director center drug evalu research 21 cfr 5 82 date may 5 1994 supplem signer murray lumpkin signer signjob act director center drug evalu research signjob frfile fr doc 9412196 file 51894 8 45 frfile bill bill code 416001f bill